Arisan, E. D. Et Al. 2014. CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells. CURRENT PHARMACEUTICAL DESIGN , vol.20, no.2 , 180-188.

Arisan, E. D., Obakan, P., Coker-Gurkan, A., Calcabrini, A., Agostinelli, E., & Unsal, N. P., (2014). CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells. CURRENT PHARMACEUTICAL DESIGN , vol.20, no.2, 180-188.

Arisan, Elif Et Al. "CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells," CURRENT PHARMACEUTICAL DESIGN , vol.20, no.2, 180-188, 2014

Arisan, Elif D. Et Al. "CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells." CURRENT PHARMACEUTICAL DESIGN , vol.20, no.2, pp.180-188, 2014

Arisan, E. D. Et Al. (2014) . "CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells." CURRENT PHARMACEUTICAL DESIGN , vol.20, no.2, pp.180-188.

@article{article, author={Elif Damla Arisan Et Al. }, title={CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells}, journal={CURRENT PHARMACEUTICAL DESIGN}, year=2014, pages={180-188} }